publication date: Dec. 7, 2018

NCI cuts programs by 5% and non-competing renewals by 3% to maintain paylines in fiscal 2019

By Matthew Bin Han Ong

NCI is cutting the budgets of divisions, offices, and centers within the institute by 5 percent to maintain funding for its Research Project Grant pool, which funds a broad range of basic research, as well as clinical trials and health services research.

In an  email sent to members of NCI’s advisory committees, NCI Director Ned Sharpless summarized the budgetary changes:

Make internal budget adjustments across NCI, including all Divisions, Offices and Centers, which will operate at 95 percent of FY 2018 levels.

Fund non-competing grant continuations at 97 percent of the committed level, with the exception of Cancer Center Support Grants, Cancer Moonshot grants, and NRSA awards.

Change the funding policy reduction to competing new and renewing grants (Type 1s and Type 2s) by 2 percent compared to FY 2018, from 17 percent to 19 percent.

Fund new grants up to and including the 8th percentile.

Maintain the [early-stage investigator] payline at 14 percent or better.

Sharpless’s email appears here, after the text of his remarks to members of the Board of Scientific Advisors and the National Cancer Advisory Board at a joint meeting Dec. 4

The institute received a $170 million boost in the fiscal year 2019 appropriations. Of these funds, $100 million is slated for the Beau Biden Cancer Moonshot—as authorized in the 21st Century Cures  Act—which leaves $70 million in general appropriations for NCI, bringing the institute’s enacted FY19 budget to $5.744 billion.

In fiscal 2018, Sharpless increased funding for the RPG pool by $146 million­, over half … Continue reading NCI cuts programs by 5% and non-competing renewals by 3% to maintain paylines in fiscal 2019

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.